Arctigenin

Arctigenin is a lignan compound derived from burdock seeds that demonstrates neuroprotective properties by inhibiting acetylcholinesterase enzyme. The compound exhibits antioxidant activity through nitrite-scavenging mechanisms and shows enhanced bioavailability when formulated in liposomal delivery systems.

Origin & History

Arctigenin is a lignan compound extracted from Arctium lappa L., commonly known as greater burdock. It is naturally present as a glycoside precursor, arctiin, which is hydrolyzed to yield arctigenin. Extraction methods include enzyme-assisted extraction and microbial fermentation.

Historical & Cultural Context

The research dossier does not include information on the traditional or historical use of arctigenin in medicinal systems. Its use in traditional practices remains undocumented in the provided sources.

Health Benefits

• Potential neuroprotective effects through acetylcholinesterase inhibition (IC₅₀ = 0.462 mg/ml) [1].
• Antioxidant properties demonstrated by nitrite-scavenging activity (IC₅₀ = 17.49 mg/ml) [1].
• Enhanced bioavailability through liposome formulation, improving absorption [1].
• High conversion efficiency in extraction methods, notably microbial fermentation [2].
• Purity of up to 99.66% achieved through supercritical CO₂ extraction [2].

How It Works

Arctigenin exerts neuroprotective effects by inhibiting acetylcholinesterase enzyme with an IC₅₀ value of 0.462 mg/ml, potentially preserving acetylcholine levels in neural tissues. The compound demonstrates antioxidant activity through nitrite-scavenging pathways (IC₅₀ = 17.49 mg/ml), helping neutralize reactive nitrogen species. Liposomal formulation significantly enhances arctigenin's bioavailability by improving cellular membrane permeability and absorption rates.

Scientific Research

The research is limited to in vitro pharmacological studies, and no human clinical trials or meta-analyses are available. Thus, the evidence is preliminary and based on laboratory findings.

Clinical Summary

Current research on arctigenin consists primarily of in vitro studies examining enzyme inhibition and antioxidant capacity. The acetylcholinesterase inhibition data comes from laboratory-based enzyme assays rather than human clinical trials. Bioavailability studies have focused on pharmaceutical formulation development using liposomal delivery systems to overcome absorption limitations. Human clinical trials evaluating therapeutic efficacy, optimal dosing, and safety profiles are currently lacking in the published literature.

Nutritional Profile

Arctigenin is a bioactive lignan compound (not a macronutrient source) isolated primarily from Arctium lappa (burdock) seeds and other Asteraceae family plants. It is not a meaningful source of macronutrients, vitamins, or minerals in typical supplemental doses. Key compositional and bioactive data: Molecular formula C₂₁H₂₄O₆, molecular weight 372.41 g/mol. Achievable purity via advanced extraction and microbial fermentation reaches up to 99.66%, indicating high-concentration isolate availability. As a lignan-class polyphenol, it exhibits phenylpropanoid structural features contributing to its antioxidant activity (nitrite-scavenging IC₅₀ = 17.49 mg/ml). Acetylcholinesterase inhibitory activity recorded at IC₅₀ = 0.462 mg/ml, indicating neuroactive potency at relatively low concentrations. Bioavailability of native arctigenin is limited due to poor aqueous solubility; liposomal encapsulation formulations have demonstrated measurably improved absorption and systemic delivery. Microbial fermentation (e.g., using gut microbiota or engineered strains) converts arctiigrin (the glycoside precursor) to arctigenin with high conversion efficiency, suggesting that bioavailability in vivo is partly dependent on gut microbiome composition. No significant fiber, protein, or micronutrient content is associated with isolated arctigenin at supplemental doses.

Preparation & Dosage

The research does not provide clinically studied dosage ranges for human use. Laboratory studies used concentrations such as 0.128 mg/ml for minimum nitrite scavenging activity. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumin, resveratrol, quercetin, omega-3 fatty acids, green tea extract

Safety & Interactions

Safety data for arctigenin supplementation in humans is limited due to the absence of comprehensive clinical trials. Potential interactions with cholinesterase inhibitor medications used for dementia treatment should be considered given arctigenin's acetylcholinesterase inhibitory activity. Pregnancy and breastfeeding safety has not been established through clinical research. Individuals taking anticoagulant medications should exercise caution, as lignans may theoretically affect bleeding risk, though specific interactions with arctigenin have not been documented.